Shelf offering
Open the filing on sec.gov
Eloxx Pharmaceuticals, Inc. (ELOX)
Nasdaq: ELOX · Biological Products, (No Diagnostic Substances) · Arlington, MA · filing with the SEC since 1997
The companyfiscal 2025, as filed
Revenue$0.00-100.0%
Net income-$6.0M-90.7%
Earnings per share$-0.49+41.7%
Operating cash flow-$6.3M-34.2%
Cash$4.8M+4210.8%
Debt$0.00
Shareholders’ equity-$11.9M+51.1%
Shares, diluted12.3M+228.5%
Return on equityn/a
The recordfrom its filings
Filings in 202650
Newest filingOct 22 · 424B3
Annual reportMar 17, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted16
Filer categoryNon-accelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.